The FDA Approves First Ketamine-Based Depression Treatment

January 21, 2025, marked a groundbreaking moment in mental health care. The U.S. Food and Drug Administration (FDA) announced its approval of SPRAVATO®, a nasal spray derived from ketamine, as the first and only standalone treatment for adults with treatment-resistant depression (TRD). This decision is a monumental shift in the world of mental health treatment, […]